Greencamp

AUGUST 16, 2018

In this comprehensive guide, we are exploring the research on using cannabis for treating Amyotrophic lateral sclerosis (ALS)—a rare neuron disease that targets the motor neurons in the body. Exploring the available research on ALS and cannabinoids. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies).

Strains 94

Strains Cannabinoids Research and Development Indica 94

CannaTech

SEPTEMBER 23, 2019

This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Furthermore, pharmaceutical companies often fund and initiate randomised clinical trials to validate their drugs.

Patients 79

Patients Policy Clinical Trials Research and Development 79

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. Additionally, they may help slow the growth of certain types of cancer cells, though further research is needed.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

AUGUST 26, 2022

Several companies are facilitating the development of this product. More research is still needed to explore this uncharted territory. CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. However, deeper research is needed to better understand its roles. billion in 2021.

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 40

Epilepsy Clinical Trials Research and Development Pharmaceutical 40

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 119

Research and Development Education Agriculture Patients 119

LifeCannMD

FEBRUARY 27, 2024

The Science Behind Medical Marijuana and Its Effects on Epileptic Seizures Medical Marijuana has garnered significant attention for its benefits in treating epilepsy and seizures. Inflammation in the brain is thought to contribute to the development and persistence of seizures.

Clinical Trials 59

Clinical Trials Epilepsy Marijuana Research and Development 59

Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Mack, Chairman and CEO of Virpax.

Epilepsy 40

Epilepsy Research and Development Clinical Trials Chronic Pain 40

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Major research hospitals such as Montefiore in New York now use cannabis for treating cancer and HIV, as well as make new studies.

Treatment 49

Treatment Clinical Trials Research and Development Cannabinoids 49

MMJ Recs

DECEMBER 28, 2023

In this article, we’ll talk about a few of the most common conditions for which medical marijuana is prescribed, exploring the growing body of research and real-world experiences that contribute to its acceptance as a viable therapeutic option.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc. 646) 421-9523.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

DECEMBER 23, 2021

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. However, regulations are constantly shifting.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

DECEMBER 18, 2019

Notably, the increase comes after the company recently broke into the European pharma-market after getting green-lighted from the Irish Government to sell its phytocannabinoid-derived “CannEpil” product to epilepsy sufferers. Both products are proprietary medicinal drugs developed internally through MGC’s research and development divisions.

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Prior to this week, the U.S.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. Marijuana law reform advocates and many medical researchers have been fighting to change marijuana’s Schedule I classification for years. Schedule I classification typically pertains to narcotic substances with no medical value.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! government classified all cannabis varieties, including hemp, as Schedule I under the Controlled Substances Act (despite decades of agricultural research detailing its differences from marijuana). What makes CBD special? In 1970, the U.S. CBD & Epidiolex.

CBD 105

CBD DEA Research and Development Hemp 105

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We This product candidate is being funded through a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS).

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Major research hospitals such as Montefiore in New York now use cannabis for treating cancer and HIV, as well as make new studies.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

SEPTEMBER 6, 2021

The steadily aging population across the globe has played a significant role in driving the demand for medical cannabis as geriatric patients are more likely to develop chronic illnesses and require more physician visits. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications.

Chronic Pain 66

Chronic Pain Research and Development Clinical Trials Epilepsy 66

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Food and Drug Administration (“FDA”). Forward-Looking Statement.

Research and Development 40

Research and Development Clinical Trials Pharmaceutical Chronic Pain 40

Cannabis Law Report

JANUARY 26, 2022

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 10, 2021

– Multiple Contracts Awarded to Support the Development and Manufacturing of Envelta (NES100) – BERWYN, Pa.–(BUSINESS IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (CRADA) with NCATS entered into by Virpax in August of 2020. “We

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

The Joint Blog

JANUARY 12, 2020

However, researchers warn that not only are not all CBD pet products made equally, but some contain no CBD at all. You’d be astounded by the analysis we’ve seen of products on the shelf with virtually no CBD in them,” said Cornell University veterinary researcher Joseph Wakshlag: He studies therapeutic uses for the compound.

Pets 36

Pets CBD Clinical Trials Research and Development 36

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 29, 2019

For instance, THC has shown the potential to help in the treatment of conditions like PTSD, depression, eating disorders, and epilepsy. Preliminary research has also shown that CBD has the potential to help patients with Parkinson’s and Alzheimer’s diseases. That’s why some people choose THC oil. THC Oil Benefits. THC Oil Effects.

Oil 80

Oil THC Cannabinoids Research and Development 80

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 40

Cannabinoids Clinical Trials Research and Development Supply Chain 40

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Otherside Farms

APRIL 14, 2020

Research on CBD ( cannabidiol ) shows that it has vast therapeutic properties. The findings were confirmed by similar research conduction in the following year. The findings were confirmed by similar research conduction in the following year. In June of 2019, the FDA in the U.S.

CBD 52

CBD Research and Development Sleep Clinical Trials 52

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Cannabis Law Report

NOVEMBER 24, 2019

Recommendations for research. Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. potential impact on structural and functional brain development. Recommendations. Rationale and impact.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

JULY 12, 2019

By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

MMJ Recs

DECEMBER 17, 2023

Here’s some insight into what the program involves: Intractable Epilepsy Focus: The TCUP is highly focused, primarily catering to individuals diagnosed with one of a specific number of qualifying conditions (more on this below). Current Texas Medical Marijuana Regulations CBD laws in Texas are governed by the Compassionate Use Program.

Law 52

Law Clinical Trials Dispensary Programs 52

MMJ Recs

JULY 5, 2024

Understanding THC’s mechanisms and clinical implications is crucial as researchers continue to uncover its therapeutic potential and limitations in medical settings. Neurological Disorders Research suggests THC may benefit neurological conditions such as epilepsy, multiple sclerosis (MS), and Parkinson’s disease.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52